Effect of Maalox® on the bioavailability of oral gemifloxacin in healthy volunteers

Chemotherapy

Volumn 45, Issue 6, 1999, Pages 504-511

  Allen, Ann ^a,b   Vousden, Marika ^a   Porter, Angela ^a   Lewis, Anastasia ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Pharmacokinetics Department SmithKline Bcecham Pharmaceuticals   (United Kingdom)

Author keywords

Antacid; Drug interactions; Fluoroquinolone; Gemifloxacin; Pharmacokinetics

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; ALUMINUM HYDROXIDE; ANTIINFECTIVE AGENT; MAGNESIUM HYDROXIDE; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; ERYTHEMA; HEADACHE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; ADOLESCENT; BIOAVAILABILITY; CROSSOVER PROCEDURE; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTACIDS; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FLUOROQUINOLONES; HUMANS; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; NAPHTHYRIDINES;

EID: 0033220053     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007245     Document Type: Article

References (21)

1. Goldstein F, Bryskier A, Appelbaum PC, Bauernfeind A, Jacobs MR, Schito G-C, Wise R: The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens, Clin Microbiol Infect 1998;4(suppl2):2S8-2S18.
2. Moore T, Niconovich N, Coleman K: SB-265805 (LB20304a): In-vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998, San Diego, CA, USA. Poster F-098.
3. Critchley IA, Broskey J, Coleman K: SB-265805 (LB20304a): In-vitro activity, intracellular accumulation and killing of Legionella pneumophila in human macrophages. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998, San Diego, CA, USA. Poster F-100.
4. Smirnov A, Wellmer A, Gerber J, Maier K, Henne S, Nau R: Gemifloxacin is effective in experimental pneumococcal meningitis. European Congress of Clinical Microbiology and Infectious Diseases, 1999, Berlin, Germany. Poster 223.
5. Allen A, Bygate E, Teillol-Foo M, Oliver S, Johnson M, Ward C: Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers; in: Abstracts from the 21st International Congress of Chemotherapy, Birmingham, UK. J Antimicrob Chemother 1999;44(suppl A): 137:Poster440.
6. Allen A, Bygate E, Teillol-Foo M, Oliver S, Johnson M, Ward C: Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers; in: Abstracts from the 21st International Congress of Chemotherapy, Birmingham, UK. J Antimicrob Chemother 1999;44(suppl A):133:Poster 418.
7. Hurwitz A: Antacid therapy and drug kinetics. Clin Pharmacokinet 977;2:269-280.
8. Jaehde U, Sörgel F, Koch HU, Stephan U, Gottschalk B, Schunack W: Gastrointestinal and hepatic drug interactions with pefloxacin, a new quinolone. Clin Pharmacol Ther 1987;42:166.
9. Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, Olschewski T, Borner K, Koeppe T: Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis 1988;10(suppl 1):S138-S139.
10. Teng R, Dogolo LC, Willavize SA, Vincent J, Friedman HL: Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997;39(suppl B):93-97.
11. Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ: Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989;33:99-102
12. Grasela TH, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, Schultz RW, Lebsack ME, Kinkel AW: Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989;33:615-617.
13. Granneman GR, Stephan U, Birner B, Sörgel F, Mukherjee D: Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet 1992;22(suppl 1): 83-89.
14. Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yashke CC: Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother 1990;34: 931-933.
15. Lomaestro BM, Bailie GR: Quinolone-cation interactions: a review. Ann Pharmacother 1991;25:1249-1258.
16. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978;6:539-547.
17. Nix DE, Watson WA, Lener ME, Frost RW, Krol G, Goldstein H, Lettieri J, Schentag JJ: Effects of aluminium and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-705.
18. Nix DE, Wilton JH, Schentag JJ, Parpia SH, Norman E, Goldstein HR: Inhibition of norfloxacin absorption by antacids and sucralfate. Rev Infect Dis 1989;11(suppl 5): S1096.
19. Shimada J, Shiba K, Oguma T, Miwa H, Yoshimura Y, Nishikawa T, Okabayashi Y, Kitagawa T, Yamamoto S: Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother 1992;36:1219-1224.
20. Flor S, Guay DRP, Opsahl JA, Tack K, Matzke GR: Effects of magnesium-aluminium hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 1990;34: 2436-2438.
21. Brouwers JRBJ: Drug interactions with quinolone antibacterials. Drug Safety 1992;7:268-281.